1. Angiotensin II: An amplifier of cardiovascular risk

   • Massimo Volpe

   Invited Commentary Pages: 247 - 248

2. Web alert

   News Pages: 249 - 250

3. Literature alert

   Abstract Pages: 251 - 252

4. Clinical Trials Report

   • Helmy M. Siragy

   BriefCommunication Pages: 255 - 256

5. Are angiotensin receptor blockers neuroprotective?

   • Christa Thöne-Reineke
   • Mathias Zimmermann
   • Thomas Unger

   OriginalPaper Pages: 257 - 266

6. Combination therapy as first-line treatment for hypertension

   • Irene Gavras
   • Talma Rosenthal

   OriginalPaper Pages: 267 - 272

7. Hypertension management in patients with diabetic nephropathy

   • Anthony L. McCall

   OriginalPaper Pages: 272 - 279

8. Mineralocorticoid receptor antagonists and hypertension: Is there a rationale?

   • Olga Gumieniak
   • Gordon H. Williams

   OriginalPaper Pages: 279 - 287

9. Clinical Trials Report

   • Michael A. Weber
   • Domenic A. Sica

   BriefCommunication Pages: 291 - 292

10. Compelling drug indications in diabetic and nondiabetic nephropathy

    • Eberhard Ritz
    • Ralf Dikow
    • Martin Zeier

    OriginalPaper Pages: 293 - 299

11. Combined antihypertensive and lipid-lowering treatment

    • Maurizio Cesari
    • Achille C. Pessina

    OriginalPaper Pages: 300 - 306

12. Protection against stroke and dementia: An update on the latest clinical trial evidence

    • Bryan Williams

    OriginalPaper Pages: 307 - 313

13. Lead-induced hypertension: Role of oxidative stress

    • Nosratola D. Vaziri
    • Domenic A. Sica

    OriginalPaper Pages: 314 - 320

14. The relationship between exposure to violence and blood pressure mechanisms

    • Dawn K. Wilson
    • Wendy Kliewer
    • Domenic A. Sica

    OriginalPaper Pages: 321 - 326

15. Aldosterone-receptor antagonism and end-stage renal disease

    • Niall McLaughlin
    • Todd W. B. Gehr
    • Domenic A. Sica

    OriginalPaper Pages: 327 - 330